Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethyl eicosapentaenoic acid/rosuvastatin

Next Previous
Drug Profile

Ethyl eicosapentaenoic acid/rosuvastatin

Alternative Names: AMR-102; Ethyl eicosapentaenoic acid/rosuvastatin - Amarin; Icosapent ethyl/rosuvastatin - Amarin; Vascepa/rosuvastatin - Amarin

Latest Information Update: 13 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amarin Corporation
  • Class Antidementias; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Antivirals; Eicosanoids; Esters; Fluorobenzenes; Omega 3 fatty acids; Pyrimidines; Reactive oxygen species; Small molecules; Sulfonamides; Vascular disorder therapies
  • Mechanism of Action HMG-CoA reductase inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hyperlipidaemia

Most Recent Events

  • 13 Mar 2023 Phase I clinical trial is still ongoing in Hyperlipidaemia in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hyperlipidaemia in USA (PO)
  • 21 Jun 2013 Safety and pharmacokinetics data from a phase I trial in healthy volunteers released by Amarin
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top